Xenetic Biosciences, Inc. (XBIO) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Xenetic Biosciences, Inc. (XBIO) Bundle
Looking to evaluate the intrinsic value of Xenetic Biosciences, Inc.? Our (XBIO) DCF Calculator integrates real-world data with comprehensive customization features, allowing you to adjust forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .4 | 1.2 | 1.7 | 2.5 | 4.4 | 7.7 | 13.4 | 23.3 | 40.5 |
| Revenue Growth, % | 0 | 2460.31 | 165.64 | 47.06 | 48.8 | 73.97 | 73.97 | 73.97 | 73.97 | 73.97 |
| EBITDA | -9.6 | -4.7 | -5.7 | -6.7 | -4.5 | -4.4 | -7.7 | -13.4 | -23.3 | -40.5 |
| EBITDA, % | -56111.35 | -1074.23 | -492.06 | -393.57 | -177.79 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .0 | .0 | .0 | .0 | .0 | 1.0 | 1.7 | 3.0 | 5.2 | 9.0 |
| Depreciation, % | 161.06 | 6.6 | 3.06 | 1.58 | 0 | 22.25 | 22.25 | 22.25 | 22.25 | 22.25 |
| EBIT | -9.6 | -4.7 | -5.7 | -6.7 | -4.5 | -4.4 | -7.7 | -13.4 | -23.3 | -40.5 |
| EBIT, % | -56272.41 | -1080.83 | -495.12 | -395.15 | -177.79 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 10.4 | 11.5 | 18.2 | 13.1 | 9.0 | 4.4 | 7.7 | 13.4 | 23.3 | 40.5 |
| Total Cash, percent | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | .9 | .3 | .4 | .3 | .2 | 2.1 | 3.6 | 6.2 | 10.8 | 18.8 |
| Accounts Payable, % | 5456.04 | 74.93 | 31.23 | 16.83 | 9.48 | 46.49 | 46.49 | 46.49 | 46.49 | 46.49 |
| Capital Expenditure | .0 | .0 | .0 | -.5 | .0 | -.3 | -.5 | -.8 | -1.4 | -2.4 |
| Capital Expenditure, % | 0 | 0 | 0 | -29.29 | 0 | -5.86 | -5.86 | -5.86 | -5.86 | -5.86 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -12.0 | -3.7 | -5.6 | -6.6 | -4.5 | -4.2 | -7.3 | -12.7 | -22.1 | -38.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -11.0 | -4.3 | -5.6 | -7.1 | -4.6 | -1.7 | -4.5 | -7.9 | -13.7 | -23.8 |
| WACC, % | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -29.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -24 | |||||||||
| Terminal Value | -185 | |||||||||
| Present Terminal Value | -91 | |||||||||
| Enterprise Value | -121 | |||||||||
| Net Debt | -9 | |||||||||
| Equity Value | -112 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | -73.19 |
What You Will Get
- Real Xenetic Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Xenetic Biosciences, Inc. (XBIO).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to (XBIO).
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Xenetic's fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections relevant to (XBIO).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for (XBIO).
Key Features
- Comprehensive Data Access: Xenetic Biosciences' historical financial records and pre-filled projections.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Observe the intrinsic value of Xenetic Biosciences recalculating instantly.
- Intuitive Visual Displays: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable resource for analysts, investors, and finance professionals.
How It Works
- 1. Download the Model: Obtain and open the Excel template featuring Xenetic Biosciences, Inc.'s (XBIO) financial data.
- 2. Adjust Key Inputs: Modify essential variables such as revenue growth, discount rates, and investment expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes the intrinsic value and net present value (NPV).
- 4. Explore Different Scenarios: Evaluate various projections to understand a range of valuation possibilities.
- 5. Present with Assurance: Share professional valuation analyses to enhance your strategic decisions.
Why Choose Xenetic Biosciences, Inc. (XBIO)?
- Innovative Solutions: Pioneering advanced drug delivery technologies to enhance therapeutic outcomes.
- Proven Expertise: A dedicated team with extensive experience in biopharmaceutical development.
- Robust Pipeline: A diverse range of products in various stages of development to meet market needs.
- Commitment to Quality: Adherence to the highest standards in research and manufacturing processes.
- Collaborative Partnerships: Strong alliances with industry leaders to drive innovation and growth.
Who Should Use This Product?
- Biotechnology Students: Understand drug development processes and apply them to real-world case studies.
- Researchers: Utilize advanced models to enhance your studies in biotech innovations.
- Investors: Evaluate your investment strategies and analyze valuation metrics for Xenetic Biosciences, Inc. (XBIO).
- Market Analysts: Optimize your analysis with a comprehensive, adaptable financial model tailored for biotech firms.
- Entrepreneurs: Learn from the strategies used by established biotech companies like Xenetic Biosciences, Inc. (XBIO).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Xenetic Biosciences historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models that illustrate intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate thorough analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Xenetic Biosciences, Inc. (XBIO).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions for easy result analysis.